DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1889)

Ulcerative Colitis | Landscape & Forecast | Disease Landscape & Forecast

Ulcerative Colitis | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

MARKET OUTLOOK

The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The anticipated entry of first-in-UC oral therapies for the moderate to severe population, together with additional emerging agents with novel MOAs and a general increase in the use of biologics to maintain disease control, will help drive market growth. In contrast to these factors, the expected generic entry of leading branded conventional agents (e.g., Shire’s Lialda), continuing generic erosion of other conventional agents, and the additional entries and expanded use of less-expensive biosimilar TNF-alpha inhibitors (e.g., Pfizer’s Inflectra, Amgen’s Amjevita) will constrain the UC market. Indeed, given the increasing competition in the UC market—for both branded and generic/biosimilar agents—emerging therapies looking to penetrate this market will need to be clearly differentiated from competitors.

QUESTIONS ANSWERED

  • What are the similarities and differences in how U.S., European, and Japanese gastroenterologists treat UC?
  •  What will be the impact of the anticipated entry of generics for the remaining key branded conventional agents (e.g., Lialda, Valeant’s Apriso)?
  • How do physicians currently perceive biosimilar agents, and what impact are these agents expected to have on the UC market?
  • What do KOLs think about key emerging therapies (e.g., Pfizer’s Xeljanz, Roche/Genentech’s etrolizumab, and Celgene’s ozanimod), and where do they see these agents fitting into the treatment algorithm?

PRODUCT DESCRIPTION

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • December 2018
      • September 2018
      • August 2018
      • June 2018
      • November 2017
      • August 2017
      • May 2017
      • February 2017
        • Expert Analysis: Inflectra's impact on U.S. immune markets
        • Expert Analysis: NOR-SWITCH data impact on U.S. uptake of Inflectra
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Ulcerative Colitis?
        • What Factors Are Constraining the Market for Ulcerative Colitis?
      • Drug-Class-Specific Trends
        • TNF-Alpha Inhibitors
        • Cell Adhesion Molecule Inhibitors
        • Janus-Activated Kinase Inhibitors
        • Interleukin Inhibitors
        • Sphingosine-1-Phosphate Receptor Modulators
        • Aminosalicylates
        • Corticosteroids
        • Immunosuppressants
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Key Findings
        • Expert Insight
        • Disease Overview
      • Etiology
        • The Immune Response
      • The Inflammatory Cascade
        • Cytokines
        • Lipid Mediators
        • Cell Adhesion Molecules
        • Janus-Activated Kinase
        • Sphingosine-1-Phosphate Receptors
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Prevalent Cases of Ulcerative Colitis
        • Diagnosed Cases of Ulcerative Colitis
        • Drug-Treated Cases of Ulcerative Colitis
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Aminosalicylates
        • Corticosteroids
        • Immunosuppressants
        • TNF-Alpha Inhibitors
        • CAM Inhibitors
        • JAK Inhibitors
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Ulcerative Colitis
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Ulcerative Colitis
        • Janus Activated Kinase Inhibitors
        • Cell Adhesion Molecule Inhibitors
        • Sphingosine-1-Phosphate Receptor Modulators
        • Interleukin Inhibitors
        • DNA-Based Immunomodulators
        • Mucoprotein Stimulants
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Ulcerative Colitis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Ulcerative Colitis Bibliography

Already a Client? Log in to access this report.

  • Pub Date: December 2018
  • Author(s): Qinghui Yu, PhD; Abey John, MPH; Ritesh Gupta, PhD
  • Qinghui Yu is a business insights analyst at Decision Resources Group. She has authored market research reports analyzing market trends in autoimmune diseases. Prior to joining Decision Resources Group, Dr. Yu worked as a senior analyst for a life science consulting firm, where she worked on a range of projects providing strategic growth advice to clients in life science ;Qinghui Yu holds a in Neuroscience from Columbia University.

  • Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country. Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.

  • Ritesh Gupta is a Lead Analyst on the immune and inflammatory disorders team at Decision Resources Group, whose work focuses primarily on Psoriatic Arthritis, Ulcerative Colitis and Crohn’s Disease. He holds a degree in Cell Biology from Max Delbrück Center for Molecular Medicine, Berlin, where he worked on development of novel inhibitors for HGF/MET signaling pathways. Prior to joining DRG, Ritesh has worked as an assistant manager with BioXcel corporation and provided insights on various consulting projects. He was also associated with GVK Biosciences and worked on drug repurposing projects.

Purchase Report

Recent reports:
You may also be interested in: